Современные представления о патогенезе депрессии и подходы к антидепрессивной терапии (на примере коаксила)


Цитировать

Полный текст

Аннотация

В обзоре рассматриваются современные теории развития депрессии и клинические проявления ее, а также факторы, обуслoвливающие вероятность развития депрессии. Приводятся сведения о структурных и функциональных изменениях головного мозга, наблюдаемых при депрессии. Сообщаются данные о тактике антидепрессивной терапии в целом и при применении коаксила в частности.

Об авторах

Нина Аркадьевна Тювина

ММА им. И. М. Сеченова

Email: natuvina@yandex.ru
Кафедра психиатрии и медицинской психологиипроф; ММА им. И. М. Сеченова

N A Tyuvina

Список литературы

  1. Kessler R. C., McGonagle K. A., Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry. 1994; 51: 8-19.
  2. Kasper S., McEven B. S. Neurobiological and clinical effects of the antidepressant tianptine. CNS Drugs 2008; 22 (1): 15- 26.
  3. Мосолов С. Н. Клинико-фармакологические свойства современных антидепрессантов. Психиатр. и психофармакотер. 2002; прил. № 1: 3-7.
  4. Danlop B. W., Nemeroff C. B. The role of dopamine in the pathophysiology of depression. Arch. Gen. Psychiatry 2007; 64: 327.
  5. Hirschfeld R. M. History and evolution of the monoamine hypothesis of depression. J. Clin. Psychiatry 2000; 61 (suppl. 6): 4-6.
  6. Pinder R. M. On the feasibility of designing new antidepressants. Hum. Psychopharmacol. 2001; 16: 53-59.
  7. Hindmarch I. Beyond the monoamine hypothesis: mechanisms, molecules and methods. Eur. Psychiatry 2002; 17 (suppl. 3): 294-299.
  8. van Praag H. M. Can stress cause depression. Progr. Neuropsychopharmacol. Biol. Psychiatry 2004; 28: 891-907.
  9. McEven B. S., Chattarji S. Molecular mechanisms of neuroplasticity and pharmacological implications: the example of tianeptine. Eur. Neuropsychopharmacol. 2004; 14 (suppl. 5): S497-S502.
  10. Aberg N. D., Brywe K. G., Isgaard J. Aspects of growth hormone and insulin-like growth factor-I related to neuroprotection, regeneration, and functionalplasticity in the adult brain. Sci. Wld J. 2006; 6: 53-80.
  11. Duman R. S., Montegia L. S. A neurotrophic model for stressrelated mood disorders. Biol. Psychiatry 2006; 59 (12): 1116- 1127.
  12. Duman R. S. Neuronal plasticity: consequensces of stress and actions of antidepressant treatment. Dialog. Clin. Neurosci. 2004; 6 (2): 157-169.
  13. Sheline Y. I., Mittler B. L., Mintum M. A. The hipocampus and depression. Eur. Psychiatry 2002; 17 (suppl. 3): 300-305.
  14. Kasper S. Neuroplasticity and the treatment of depression. Neuropsychiatr. Dis. Treat. 2006; 2 (S2): 14-20.
  15. Sheline Y. I., Sanghavi M., Mintum M. A. et al. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J. Neurosci. 1999; 19: 5034-5043.
  16. Bremer J. D., Vythilingam M., Vermetten E. et al. Reduced volume of orbitolfrontal cortex in major depression. Biol. Psychiatry 2002; 51: 273-279.
  17. Cotter D., Mackay D., Landau S. et al. Reduced glial cell dencity and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch. Gen. Psychiatry 2001; 58: 545-553.
  18. Rajkowska G., Miguel-Hidalgo J. J., Wei J. et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol. Psychiatry 1999; 45: 1085-1098.
  19. Ongur D., Drevets W. C., Price J. L. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc. Natl. Acad. Sci. USA 1998; 95: 13290-13295.
  20. Hamidi M., Drevets W. C., Price J. L. Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol. Psychiatry 2004; 55: 563-569.
  21. Dreverts W. C. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Progr. Brain Res. 2000; 126: 413-431.
  22. Dreverts W. C., Price J. L., Bardgett M. E. et al. Glucose metabolism in the amygdala in depression: relationship to diagnostic subtype and plasma Cortisol levels. Pharmacol. Biochem. Behav. 2002; 71 (3): 431-447.
  23. Mac Queen G. M., Campbell S., McEven B. S. et al. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc. Natl. Acad. Sci. USA 2003; 100: 1387-1392.
  24. Frodl T., Meizenzahl E. M., Zetzsche T. et al. Hippocampal changes in patients with a first episode of major depression. Am. J. Psychiatry 2002; 159: 1112-1118.
  25. Frodl T., Meizenzahl E. M., Zetzsche T. et al. Enlargement of the amygdale in patients with a first episode of major depression. Biol. Psychiatry 2002; 51: 708-714.
  26. McEven B. S. Mood disorders and alostatic load. Biol. Psychiatry 2003; 54: 200-207.
  27. Bremer J. D., Narayan M., Andersen E. R. et al. Hippocampal volume reduction in major depression. Am. J. Psychiatry 2000; 157: 115-118.
  28. Sheline Y. I., Gado M. H., Price J. L. Amygdala core nuclei volumes are decreased in recurrent major depression. NeuroReport 1998; 9: 2023-2028.
  29. Von Gunten A., Fox N. C., Cipolotti L. et al. A volumetric study of hippocampus and amygdala in depressed patients with subjective memory problems. J. Neuropsychiatry Clin. Neurosci. 2000; 12: 493-498.
  30. Campbell S., Marriott M., Nahmias C. et al. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am. J. Psychiatry 2004; 161: 598-607.
  31. Sheline Y. I., Wang P. W., Gado M. H. et al. Hippocampal atrophy in recurrent major depression. Proc. Natl. Acad. Sci. USA 1996; 93: 3908-3913.
  32. Erecinska M., Silver J. A. Metabolism and role of glutamate in mammalian brain. Progr. Neurobiol. 1990; 35 (4): 245-296.
  33. Zarate Jr. S. A., Du J., Quiroz J. et al. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of glutamatergic system. Ann. N. Y. Acad. Sci. 2003; 1003: 273-291.
  34. Lowy M. T., Gault M. T., Yamamoto B. K. Adrenalectomy attenuates stress-induced elavations in extracellulars glutamate concentrations in the hippocampus. J. Neurochem. 1993; 61: 1957-1560.
  35. Lowy M. T., Wittenberg L., Yamamoto B. K. Effects of acute stress on hippocampal glutamate levels and spectrin proteolysis in young and age rats. J. Neurosci. 1995; 65: 268-274.
  36. Reznikov L. R., Grillo C. A., Piroli G. G. et al. Acute stress-mediated increased in extracellular glutamate levels in the rat amygdala: differentional effects of antidepressant treatment. Eur. J. Neurosci. 2007; 25 (10): 3109-3114.
  37. Yamamoto B. K., Regan L. P. The glutamatergic system in neuronal plasticity and vulnerability in mood disorders. Neuropsychiatr. Dis. Treat. 2006; 2 (suppl. 2): 7-13.
  38. McEven B. S., Sapolsky R. M. Stress and cognetive function. Curr. Opin. Neurobiol. 1995; 5: 205-216.
  39. Kim J. S., Schmid-Burgk W., Claus D. et al. Increased serum glutamate in depressed patients. Arch. Psychiatr. Nervenkr. 1982; 232: 229-304.
  40. Altamura C. A., Mauri M. C., Ferrara A. et al. Plasma and platelet excitatory amino acids in psychiatric disorders. Am. J. Psychiatry 1993; 150: 1731-1733.
  41. Altamura C., Maes M., Dai O. et al. Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur. Neuropsychopharmacol. 1995; 5 (suppl. 1): 71-75.
  42. Levine J., Panchalingam K., Rapoport A. et al. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol. Psychiatry 2000; 47: 1835-1853.
  43. Auer D. P., Putz B., Kraft E. et al. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol. Psychiatry 2000; 47: 305-313.
  44. Mirza Y., Tang J., Russel A. et al. Reduced anterior cingulate cortex glutamatergic concentrations in childhood major depression. J. Am. Acad. Child Adolesc. Psychiatry 2004; 43: 341-348.
  45. Sanacora G., Gueorguieva R., Epperson C. N. et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch. Gen. Psychiatry 2004; 61: 705-713.
  46. Choudary P. V., Molnar M., Evans S. J. et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc. Natl. Acad. Sci. USA 2005; 102: 15653-15658.
  47. Van der Hart M. G., Czeh B., de Biurrun G. et al. Substance P receptor antagonist and clomipramine prevent stress-induced alterations in cerebral metabolites, cytogenesis in the dentate gyrus and hippocampal volume. Mol. Psychiatry 2002; 7: 493-498.
  48. Wood G. E., Young L. T., Reagan L. P. et al. Stress-induced structural remodeling in hippocampus: prevention by lithium treatment. Proc. Natl. Acad. Sci. USA 2004; 101: 3973-3978.
  49. McEven B. S., Olie J. P. Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptane. Mol. Psychiatry 2005; 10 (6): 525-537.
  50. McEven B. S., Magarinos A. M., Reagan L. P. Structural plasticity and tiaptine: cellular and molecular targets. Eur. Psychiatry 2002; 17 (suppl. 3): 318-330.
  51. Kole M. H., Swan L., Fuchs E. The antidepressant tianeptine persistently modulates glutamate receptor currents of the hippocampal CA3 commissural associational synapse in chronically stressed rats. Eur. J. Neurosci. 2002; 16: 807-816.
  52. Regan L. P., Rossel D. R., Wood G. E. et al. Chronic restraint stress up-regulates GLT-1 mRNA and protein expression in the rat hippocampus: reversal by tianeptine. Proc. Natl. Acad. Sci. USA 2004; 101: 2179-2184.
  53. Watnabe Y., Gould E., Cameron H. A. et al. Tianeptine attenuates stress-induced morthological changes in the hippocampus. Eur. J. Pharmacol. 1992; 222: 157-162.
  54. Lucassen P. J., Fuchs E., Czeh B. Antidepressant treatment with tianeptine reduces apoptosis in the hippocampal denate gyrus and temporal cortex. Biol. Psychiatry 2004; 55: 789-796.
  55. Kasper S., Olie J. P. A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression. Eur. Psychiatry 2002; 17 (suppl. 3): 331-340.
  56. Guelfi J. D., Pichot P., Dreyfus J. F. Efficacy of tianeptine in anxious-depressed patients: results of a controlled multicentre study versus amitriptyline. Neuropsychobiology 1989; 22 (1): 41-48.
  57. Invernizzi G., Aguglia E., Bertolino A. et al. The efficacy and safety of tianeptine in the treatment of depressive disorder: results of a controlled double-blind multicentre study vs. amitriptyline. Neuropsychobiology 1994; 30 (2-3): 85-93.
  58. Loo H., Malka R., Defrance R. et al. Tianeptine and amitriptyline: controlled double-blind trial in depressed alcoholic patients. Neuropsychobiology 1988; 19 (2): 79-85.
  59. Annseau M., Bataille M., Briole G. et al. Controlled comparison of tianeptine, alprazolam and mianserin in the treatment of adjustment disorders with anxiety and depression. Hum. Psychopharmacol. 1996; 11: 293-298.
  60. Brion S., Audrain S., de Bodinat C. Major depressive episodes in patients over 70 years of age: evaluation of the efficiency and acceptability of tianeptine and mianserin. Presse Med. 1996; 25 (9): 461-468.
  61. Alby J. M., Ferreri M., Cabane J. et al. Efficacy of tianeptine (StablonTM) for the treatment of major depression and dysthymia with somatic complaints: a comparative study versus fluoxetine (ProzacTM). Ann. Psychiatr. 1993; 8 (2): 136-144.
  62. Loo H., Saiz-Ruiz J., Costa e Silva J. et al. Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine. J. Affect. Disord. 1999; 56 (2-3): 109-118.
  63. Novotny V., Faltus F. First signs of improvement with tianeptine in the treatment of depression: an analysis of a double-blind study versus fluoxetine. Eur. Neuropsychopharmacol. 2003; 13 (suppl. 4): S230.
  64. Иванец Н. Н., Тювина Н. А., Балабанова В. В., Прупис О. В. Эффективность тианептина (коаксила) при депрессивных расстройствах невротического и субпсихотического уровня. Психиатр. и психофармакотер. 2002; прил. № 1: 7-9.
  65. Мосолов С. Н., Вовин Р. Я., Пантелеева Г. П. и др. Клиническая эффективность и переносимость препарата "Коаксил" (тианептин) при терапии депрессии. Журн. неврол. и психиатр. 2003; 8: 29-34.
  66. Тювина Н. А., Балабанова В. В. Место коаксила в терапии депрессивных расстройств климактерического периода у женщин. Психиатр. и психофармакотер. 2002; прил. № 1: 11-14.
  67. Нуллер Ю. Л., Жарницкая Д. З., Ишукова Л. В. Лечение коаксилом депрессии у больных пожилого возраста. Психиатр. и психофармакотер. 2002; прил. № 1: 9-11.
  68. Dalery J., Dagens-Lafont V., De Bodiant C. Efficacy tianeptine vs placebo in the long-term treatment (16.5 months) of unipolar major reccurrent depression. Hum. Psychopharmacol. 2001; 16 (suppl. I): S39-S47.
  69. Тювина Н. А., Крук Я. В. Сравнительное исследование эффективности амитриптилина, финлепсина и коаксила при профилактической терапии рекуррентного депрессивного расстройства. Психиатр. и психофармакотер. 2005; 3: 160-164.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО "Консилиум Медикум", 2009

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Адрес издателя

  • 127055, г. Москва, Алабяна ул., 13, корп.1

Адрес редакции

  • 127055, г. Москва, Алабяна ул., 13, корп.1

По вопросам публикаций

  • +7 (926) 905-41-26
  • editor@ter-arkhiv.ru

По вопросам рекламы

  • +7 (495) 098-03-59

 

  


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах